Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EOC315 plus XELOX vs placebo plus XELOX in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma
CTR20182460Phase 2Active
- Sponsor
- Eden Biologics, Inc.
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of telatinib in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Eden Biologics, Inc.. Started Dec 2018; status: active.
02
Drugs
telatinib
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20182460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20182460.